

EDITORIAL • RÉDACTION

Editor • Rédacteur

John Hoey (john.hoey@cma.ca)

Deputy Editor • Rédactrice adjointe

Anne Marie Todkill (annemarie.todkill@cma.ca)

Associate Editors • Rédacteurs associés

Tom Elmslie; Ken Flegel;
K.S. Joseph; Anita Palepu;
Peter Singer; Erica Weir;
James Hanley (Biostatistics • Biostatistique)

Editorial Fellow • Boursière en rédaction médicale

Eric Wooltorton (eric.wooltorton@cma.ca)

Managing Editor • Rédactrice administrative

Jennifer Douglas (jennifer.douglas@cma.ca)

News Editor

Rédacteur, informations générales

Patrick Sullivan (patrick.sullivan@cma.ca)

Editors • Rédacteurs

Patricia Lightfoot (patricia.lightfoot@cma.ca)
Glenda Proctor (glenda.proctor@cma.ca)
Jennifer Raiche (jennifer.raiche@cma.ca)
Kate Schissler (kate.schissler@cma.ca)
Barbara Sibbald (barbara.sibbald@cma.ca)
Steven Wharry (steve.wharry@cma.ca)

Editorial Administrator • Administratrice de rédaction

Carole Corkery (carole.corkery@cma.ca)

Editorial Assistants • Assistantes à la rédaction

Erin Archibald (erin.archibald@cma.ca)
Wilma Fatica (wilma.fatica@cma.ca)
Melanie Mooy (melanie.mooy@cma.ca)
Joyce Quintal (joyce.quintal@cma.ca)

Translation Coordinator

Coordonnatrice de la traduction

Marie Saumure

Contributing Editors • Rédactrices invitées

Gloria Baker; Charlotte Gray; Peggy Robinson

Editorial Board • Conseil de rédaction

Paul W. Armstrong (Edmonton)
Neil R. Cashman (Toronto)
Deborah J. Cook (Hamilton)
Raisa B. Deber (Toronto)
William Ghali (Calgary)
Frank R. de Grujil (Utrecht, the Netherlands)
David H. Feeny (Edmonton)
Judith G. Hall (Vancouver)
Carol P. Herbert (London)
Neill Iscoe (Toronto)
Alejandro R. Jadad (Toronto)
Jerome P. Kassirer (Boston)
Finlay A. McAlister (Edmonton)
Allison J. McGeer (Toronto)
Harriet L. MacMillan (Hamilton)
Olli S. Miettinen (Montréal)
David Moher (Ottawa)
Susan Phillips (Kingston)
André Picard (Montréal)
Donald A. Redelmeier (Toronto)
Martin T. Schechter (Vancouver)
Richard Smith (*British Medical Journal*,
London, England)
Sander J.O. Veldhuyzen van Zanten (Halifax)
Salim Yusuf (Hamilton)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association (CMA). The CMA assumes no responsibility or liability for damages arising from any error or omission or from the use of any information or advice contained in CMAJ including editorials, studies, reports, letters and advertisements.

Tous les articles à caractère éditorial dans le JAMC représentent les opinions de leurs auteurs et n'engagent pas l'Association médicale canadienne (AMC). L'AMC décline toute responsabilité civile ou autre quant à toute erreur ou omission ou à l'usage de tout conseil ou information figurant dans le JAMC et les éditoriaux, études, rapports, lettres et publicités y paraissant.

Breast cross-examination

A few weeks ago we published a report by Nancy Baxter and the Canadian Task Force on Preventive Health Care on the effectiveness of breast self-examination (BSE) and BSE instruction in reducing breast cancer mortality.¹ The report showed that BSE can be credited with an increase in breast biopsies, but not with an increase in breast cancer survival, or even with the detection of tumours at an earlier stage. And so the Task Force has downgraded the routine teaching of BSE to a “D” recommendation: that is, there is “fair evidence” that we shouldn’t bother.

To many women, and to many health professionals, this seemed a perverse and wasteful assault on common sense. One of the most potent beliefs about cancer is that a stitch in time saves nine. Early detection has been promoted with such zeal by the medical profession and by advocacy groups that it has become a notional proxy for “prevention” and even “cure.” The benefits of mammography screening programs are taken to be real, but some researchers, taking a harder look, have pronounced them a mirage.² Now the available evidence is telling us that the benefits of BSE are, perhaps, the illusory product of wishful thinking.

Our conceptions of illness and illness management carry a heavy ideological payload. In the case of breast cancer, that ideology concerns empowerment: the empowerment of women to set the research agenda, to motivate prevention and influence care, to take control of their health. When Baxter’s article was published, women insisted in the lay media that they, not their doctors, are

finding breast cancers. “It’s in your hands,” read the headline of one such testimony.³ But was the poor prognosis of this woman’s metastatic cancer also in her hands? One could argue that the rhetoric of cancer puts an intolerable burden of responsibility and self-determination on the patient. Among the predictors of the outcome of breast cancer are such occult factors as gene mutations, cell-mediated immune responses, mitotic activity, rapidity of onset, growth rate, histology, anatomic stage, and so forth. The finding that 29% of women with stage 1A breast cancer already have micrometastases in their bone marrow⁴ should give pause to the champions of screening. The more we learn, the less we seem to know. The complexity of cancer is hardly a fair match for anyone, no matter how vigilant and well-informed she may be. We need to follow Baxter’s example in being honest about the harms, and not merely the benefits, of cancer screening and management.

Cancer screening is not a field of dreams, but a minefield of surprises and broken promises. We have a long way to go. Let’s proceed with less rhetoric and more candour. — CMAJ

References

1. Baxter N, with the Canadian Task Force on Preventive Health Care. Preventive health care, 2001 update: Should women be routinely taught breast self-examination to screen for breast cancer? *CMAJ* 2001;164(13):1837-46.
2. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? *Lancet* 2000;355(9198):129-34.
3. Crawley J. Breast exams. It’s in your hands. *Globe and Mail* [Toronto] 2001 June 28;SectA:13.
4. Braun S, Pantel K, Müller P, Janni W, Hepp F, Kantenich CRM, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. *N Engl J Med* 2001;342(8):525-33.